Pre-made Volagidemab benchmark antibody ( Whole mAb, anti-GCCR/NR3C1 therapeutic antibody, Anti-GCR/GCRST/GR/GRL Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Volagidemab biosimilar, Whole mAb, Anti-GCCR/NR3C1 Antibody: Anti-GCR/GCRST/GR/GRL therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Volagidemab is a G-protein coupled receptors (GPCR) antagonist and was discovered with Xenomouse technology, which recapitulates a human antibody response in the mouse, and the antibody sequences are fully human.
| Products Name (INN Index) | Pre-Made Volagidemab biosimilar, Whole mAb, Anti-GCCR/NR3C1 Antibody: Anti-GCR/GCRST/GR/GRL therapeutic antibody |
|---|---|
| INN Name | Volagidemab |
| Target | NR3C1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 4lf3:ED:BA/5xf1:HL:CD/5xez:CD:HL/4ers:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Amgen,REMD Biotherapeutics |
| Conditions Approved | NA |
| Conditions Active | Type 1 diabetes mellitus,Type 2 diabetes mellitus,Metabolic disorders,Glucose intolerance |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GCCR |
| Package |
